{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:22Z","timestamp":1785822442604,"version":"3.56.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["2019-2, 12567"],"award-info":[{"award-number":["2019-2, 12567"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["09150172010054"],"award-info":[{"award-number":["09150172010054"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Targeted radionuclide therapy (TRT) and immune checkpoint inhibition (ICI) could be a highly effective combination treatment due to potential synergistic effects. In this study, we investigated two clinically relevant antibody-based radiopharmaceuticals labeled with lutetium-177: [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-hG250 targeting carbonic anhydrase IX (CAIX) and rosopatamab tetraxetan ([\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-rosopatamab) targeting prostate-specific membrane antigen (PSMA). We aimed to assess whether ICI target and treatment timing influence the efficacy of TRT+ICI combinations across three syngeneic murine tumor models with distinct immunogenicity profiles. Understanding these factors is critical for optimizing combination strategies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      C57BL6 hPSMA transgenic mice bearing subcutaneous MC38-hPSMA or B16F10-hPSMA tumors were injected with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-rosopatamab. Balb\/c mice bearing subcutaneous renca-hCAIX tumors were injected with [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-hG250. Tumor growth and overall survival were evaluated for different combination treatments of hPSMA-TRT or hCAIX-TRT with aPD-1, aCTLA-4, or dual-ICI (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a010 per group). To evaluate the impact of timing on therapeutic outcomes, different concurrent and sequential treatment schedules were compared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the MC38-hPSMA model, a subtherapeutic [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-rosopatamab dose combined with aPD-1 resulted in robust anti-tumor activity. aCTLA-4 monotherapy was already curative, precluding detection of a combination effect under the conditions tested. In contrast, in the B16F10-hPSMA model, only minimal benefit was seen when combining the same radiopharmaceutical with dual-ICI. The renca-hCAIX model demonstrated differential outcomes, responding most strongly to a subtherapeutic dose of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTA-hG250 combined with dual-ICI, while combining with aPD-1 provided moderate benefit and with aCTLA-4 had no therapeutic benefit. Lastly, exploring treatment timing in the MC38-hPSMA and renca-hCAIX models revealed only limited impact on therapeutic outcome under the assessed conditions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      These findings indicate that\n                      <jats:sup>177<\/jats:sup>\n                      Lu-labeled antibodies can synergize with ICI at subtherapeutic activity levels in certain settings, supporting their potential to enhance efficacy while potentially reducing toxicity. Combination outcomes varied across tumor models and ICI targets and were likely influenced by both biological and experimental context. The impact of treatment timing appeared limited within the experimental conditions evaluated. These findings should be further explored in preclinical models incorporating mechanistic analyses, while the impact of treatment timing warrants additional investigation in clinically relevant settings. These insights highlight key factors for optimizing TRT+ICI strategies in future clinical studies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1872928","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:35:54Z","timestamp":1785821754000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of immune checkpoint inhibitor target and timing on combination treatment with antibody-based \u03b2-emitting targeted radionuclide therapy across tumor immunogenicity profiles"],"prefix":"10.3389","volume":"17","author":[{"given":"Simone C.","family":"Kleinendorst","sequence":"first","affiliation":[{"name":"Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"Oosterwijk","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Konijnenberg","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center","place":["Nijmegen, Netherlands"]},{"name":"Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou","family":"Boswinkel","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Gloudemans","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia T.M.","family":"Wenker","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Muselaers","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mulders","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Maffa","sequence":"additional","affiliation":[{"name":"Telix Pharmaceuticals Limited","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"O\u2019Hara","sequence":"additional","affiliation":[{"name":"Telix Pharmaceuticals Limited","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Wheatcroft","sequence":"additional","affiliation":[{"name":"Telix Pharmaceuticals Limited","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Twumasi-Boateng","sequence":"additional","affiliation":[{"name":"Telix Pharmaceuticals Limited","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Heskamp","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Center","place":["Nijmegen, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248062","article-title":"Combination strategies to improve targeted radionuclide therapy","volume":"61","author":"Chan","year":"2020","journal-title":"J Nucl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-4332","article-title":"Combining targeted radionuclide therapy and immune checkpoint inhibition for cancer treatment","volume":"28","author":"Kleinendorst","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264373","article-title":"Combined targeted radiopharmaceutical therapy and immune checkpoint blockade: from preclinical advances to the clinic","volume":"63","author":"Bellavia","year":"2022","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/thno.96944","article-title":"Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Kleinendorst","year":"2024","journal-title":"Theranostics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7030100","article-title":"Radiation as an in situ auto-vaccination: current perspectives and challenges","volume":"7","author":"Goto","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.021","article-title":"The 2018 Nobel Prize in Physiology or Medicine: an exemplar of bench to bedside in immunology","volume":"142","author":"Ballas","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1007\/s00259-025-07293-0","article-title":"Efficacy of combined targeted radionuclide therapy and immune checkpoint inhibition in animal tumour models: a systematic review and meta-analysis of the literature","volume":"52","author":"Kleinendorst","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00451-5","article-title":"Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000980","article-title":"Phase I study of the 177Lu-DOTA0-Tyr3-octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung","volume":"8","author":"Chul","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197146","article-title":"Carbonic anhydrase IX in renal cell carcinoma, implications for disease management","volume":"21","author":"Courcier","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00402-9","article-title":"89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.08.024","article-title":"Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"64","author":"Stillebroer","year":"2013","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.033","article-title":"Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"69","author":"Muselaers","year":"2016","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000091655.77601.0c","article-title":"Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen","volume":"170","author":"Bander","year":"2003","journal-title":"J Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-024-00699-w","article-title":"Lutetium-177 labelled anti-PSMA monoclonal antibody (Lu-TLX591) therapy for metastatic prostate cancer: treatment toxicity and outcomes","volume":"28","author":"Nguyen","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"241503","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS253","article-title":"Safety, tolerability, and dosimetry of TLX591 with best standard of care in patients with PSMA-expressing metastatic castration resistant prostate cancer (ProstACT SELECT preliminary results)","volume":"65","author":"Lenzo","year":"2024","journal-title":"J Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0561","article-title":"Reverse translating molecular determinants of anti\u2013programmed death 1 immunotherapy response in mouse syngeneic tumor models","volume":"21","author":"Georgiev","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206223","article-title":"Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments","volume":"13","author":"Yu","year":"2018","journal-title":"PloS One"},{"key":"B22","article-title":"survRM2: comparing restricted mean survival time","author":"Uno","year":""},{"key":"B23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0063","article-title":"A phase Ib study of atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer","volume":"27","author":"Fong","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-22-0306","article-title":"Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer","volume":"12","author":"Choudhury","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.667658","article-title":"Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Creemers","year":"2021","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.3.423","article-title":"Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells","volume":"191","author":"Sauter","year":"2000","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.212720","article-title":"Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer","volume":"60","author":"Schottelius","year":"2019","journal-title":"J Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/01.shk.0000142249.08135.e9","article-title":"Innate immune response in Th1- and Th2-dominant mouse strains","volume":"22","author":"Watanabe","year":"2004","journal-title":"Shock"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/2326-6066.cir-24-1191","article-title":"The effects of clinically relevant radionuclides on the activation of a type I interferon response correlate with radionuclide half-life and linear energy transfer and influence radiopharmaceutical antitumor efficacy","volume":"13","author":"Kerr","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68834-1","article-title":"Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice","volume":"17","author":"Kerr","year":"2026","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264752","article-title":"Targeted \u03b1-therapy using (225)Ac radiolabeled single-domain antibodies induces antigen-specific immune responses and instills immunomodulation both systemically and at the tumor microenvironment","volume":"64","author":"Ertveldt","year":"2023","journal-title":"J Nucl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.209510","article-title":"Combined VLA-4-targeted radionuclide therapy and immunotherapy in a mouse model of melanoma","volume":"59","author":"Choi","year":"2018","journal-title":"J Nucl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7150\/thno.54881","article-title":"Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy","volume":"11","author":"Jagodinsky","year":"2021","journal-title":"Theranostics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02606-8","article-title":"Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy","volume":"69","author":"Rouanet","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1011943","article-title":"Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy","volume":"13","author":"Denis","year":"2022","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7150\/thno.39203","article-title":"Integrin \u03b1(v)\u03b2(3)-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265391","article-title":"Addition of peptide receptor radiotherapy to immune checkpoint inhibition therapy improves outcomes in neuroendocrine tumors","volume":"64","author":"Esfahani","year":"2023","journal-title":"J Nucl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002387","article-title":"Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy","volume":"9","author":"Lejeune","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030773","article-title":"Evaluating the combination of radioimmunotherapy and immunotherapy in a melanoma mouse model","volume":"21","author":"Jiao","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s40425-019-0789-4","article-title":"Moving forward to address key unanswered questions on targeting PD-1\/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors","volume":"7","author":"Le","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872928\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:35:55Z","timestamp":1785821755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1872928\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1872928"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1872928","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1872928"}}